Feasibility of a Multi-omics Platform for Hematological Malignancies

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2+
SponsorAzienda Ospedaliero-Universitaria di Parma

About this trial

This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.

Eligibility criteria

Qualifiers

Patient aged > 2 year old

Patients previously diagnosed with hematological malignancies

Patients with clinical suspect of hematological malignancies requiring a diagnostic assessment using BM or PB samples, biopsies of lymph nodes or tissues with metastatic involvement, or other biological fluids (such as CSF, pathologic pleural effusion).

Patients with clinical suspicion of R/R onco-hematological disorder, requiring a diagnostic assessment using BM aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from lumbar puncture, tissue aspirate etc.

Disqualifiers

Age <2 year old

Patient without a diagnosis of hematological malignancy.

Trial design

Treatments tested in this trial

  • Multi-omics analyses
  • Functional tests

Treatment groups

1,040 Participants
are divided into 1 treatment group

Sponsors and collaborators

Azienda Ospedaliero-Universitaria di Parma

Lead sponsor

University of Parma

Sponsor institution